NCT07816133

Brief Summary

This study hypothesizes that the histological, immunophenotypic, and molecular characterization of atypical endometriotic lesions may be related to specific clinical and ultrasound features.Identifying potentially atypical lesions would allow for more accurate stratification of patients, distinguishing definitely benign from potentially atypical endometriosis. The targeted study of endometriosis, both typical and atypical, also with reference to the inflammatory microenvironment, as well as immunophenotypic and molecular characteristics, could allow the formulation of pathogenic hypotheses on the development and progression of atypia towards malignant neoplasms.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
32mo left

Started Oct 2026

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 7, 2026

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 11, 2026

Completed
20 days until next milestone

Study Start

First participant enrolled

October 1, 2026

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2029

Expected
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2029

Last Updated

September 11, 2026

Status Verified

September 1, 2026

Enrollment Period

2.3 years

First QC Date

September 7, 2026

Last Update Submit

September 7, 2026

Conditions

Keywords

endometriomaimmunohistochemical and molecular analysisanatomopathological analysis

Outcome Measures

Primary Outcomes (1)

  • Identification of specific histopathological, immunohistochemical and molecular biology features for definable "atypical", "preneoplastic" or "cancerized-neoplastic" lesions and the surrounding microenvironment

    through study completion, an average of 1 year

Secondary Outcomes (1)

  • Identification of specific ultrasound features of lesions described in histological examination as "atypical", "preneoplastic", or "cancerized-neoplastic"

    through study completion, an average of 1 year

Study Arms (2)

prospective observational group

Other: prospective case-control group

retrospective observational group

Other: Retrospective case-control analysis

Interventions

Single-center observational retrospective study with case collection starting June 2024

retrospective observational group

Single-center prospective observational study with recruitment of new cases for 30 months from the start of the project.

prospective observational group

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

patients undergoing laparoscopic surgery for benign or malignant (endometrial or ovarian) pathology

You may qualify if:

  • Age \> 18 years
  • Candidate patients for endometriosis surgery with deep endometriosis (intestine, LUS) and/or endometrioma localizations.
  • Patients who are candidates for surgery for established or suspected endometrial and/or ovarian neoplasm
  • Patients who have performed a level II gynecological ultrasound with an experienced operator in the preoperative process.
  • Patients where there is the technical possibility of performing a transvaginal and/or transrectal ultrasound and the patient's willingness to undergo such an investigation.
  • Signing of informed consent.

You may not qualify if:

  • Technical impossibility of performing a transvaginal ultrasound (patient virgo, patient refusal).
  • Previous neoplasms
  • Patient who does not provide their informed consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ospedale P. Pederzoli Casa di Cura Privata S.p.A.

Peschiera del Garda, Verona, 37019, Italy

RECRUITING

MeSH Terms

Conditions

Endometriosis

Condition Hierarchy (Ancestors)

Genital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 7, 2026

First Posted

September 11, 2026

Study Start

October 1, 2026

Primary Completion (Estimated)

January 1, 2029

Study Completion (Estimated)

June 1, 2029

Last Updated

September 11, 2026

Record last verified: 2026-09

Data Sharing

IPD Sharing
Will not share

Locations